ImmunoGen Inc (IMGN.OQ)
Get access to over 18 million research reports from over 1,700 sources.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
- private equity
- third-party document and information retrieval
- and much, much more…
|64||2009||Independent Chairman of the Board|
|53||2016||President, Chief Executive Officer, Director|
|61||2013||Chief Financial Officer, Executive Vice President|
|59||2015||Executive Vice President - Research, Chief Scientific Officer|
|62||2016||Executive Vice President, General Counsel, Secretary|
- BRIEF-Immunogen Says On Jan 8, Co Disclosed It Expects To Report That As Of Dec 31, 2017 It Had Cash And Cash Equivalents Of About $267.1 Mln
- BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies
- BRIEF-ImmunoGen reports Q3 loss per share $0.61
- BRIEF-Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active
- BRIEF-Immunogen prices offering of 14.5 mln common shares at $6.50 per share